Daxor gets European patent approval for blood-volume analyzer

By Elaine Rigoli

Tampa, Fla., July 20 - Daxor Corp. received notification from the European Patent Office that it has received a patent for its injection kit system, the Max-100, for use with the blood-volume analyzer BVA-100.

The company said BVA-100 works in conjunction with the Max-100 radiopharmaceutical kit, specifically designed to provide a volumetric flow-through chamber, which is a critical component of providing a precise blood-volume analysis.

The company said this system is the only semi-automated blood-volume analysis system cleared by the Food and Drug Administration for marketing in the United States.

Daxor, based in New York, is a medical instrumentation and biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.